Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ENVB, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
ENVB holds $8.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.4M/quarter from operations, an estimated runway of 10.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 70 · High
These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ENVB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | Institution (13G, 5%+) | 405,092 | 9.05% | 2026-06-30 |
| Sio Capital Management, LLC | Institution (13G, 5%+) | 330,000 | 7.37% | 2026-09-30 |
| Joseph Edward Tucker Chief Executive Officer, Director |
Insider | 271,479 | 6.07% | 2026-06-01 |
| Kevin Michael Coveney Chief Financial Officer |
Insider | 180,746 | 4.04% | 2026-06-01 |
| Lind Global Fund III LP | 5%+ holder (13G) | 141,265 | 3.16% | 2026-01-28 |
| Peter J. Facchini Chief Innovation Officer |
Insider | 27,755 | 0.62% | 2026-06-01 |
| Frank Pasqualone Director |
Insider | 26,423 | 0.59% | 2026-06-01 |
| George A. Kegler Director |
Insider | 26,418 | 0.59% | 2026-06-01 |
| Marcus Schabacker Director |
Insider | 26,418 | 0.59% | 2026-06-01 |
| Michael D Webb Director |
Insider | 26,416 | 0.59% | 2026-06-01 |
| Sheila DeWitt Director |
Insider | 26,306 | 0.59% | 2026-06-01 |
Share count 4,475,884 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENVB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →